Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yixin Decoction is a traditional Chinese medicine (TCM) herbal formulation used primarily for cardiovascular conditions, especially in the context of myocardial ischemia-reperfusion injury (MIRI). It is typically administered as a decocted mixture of multiple herbs, though the exact composition may vary by practitioner or region. Recent research highlights that polysaccharides from Shenxiong Yixin Decoction can reduce myocardial infarct size, improve cardiac function, and enhance cardiomyocyte survival following MIRI. The mechanism involves modulation of gut-derived exosomal microRNA-21 (miR-21), which is transported to the heart and helps inhibit oxidative stress and apoptosis in damaged myocardium by downregulating PDCD4 expression[1]. Clinical studies have also explored its use alongside conventional Western medicine for viral myocarditis in elderly patients[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yixin Decoction.